L-DOS47

DRUG4 trials

Sponsors

Helix BioPharma Corporation

Conditions

Lung AdenocarcinomaNon-Small Cell Lung CancerPancreas Cancer

Phase 1

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

TerminatedNCT02309892

Helix BioPharma CorporationNon-Small Cell Lung Cancer

Start: 2015-04-20End: 2019-09-20Updated: 2024-06-03

A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47

CompletedNCT02340208

Helix BioPharma CorporationNon-Small Cell Lung Cancer

Start: 2012-05-31End: 2017-12-20Updated: 2019-03-14

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

TerminatedNCT04203641

Helix BioPharma CorporationPancreas Cancer

Start: 2019-12-11End: 2024-10-24Updated: 2025-05-06

Phase 2

A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

TerminatedNCT03891173

Helix BioPharma CorporationLung Adenocarcinoma

Start: 2019-02-19End: 2020-05-22Updated: 2022-08-12

Related Papers

Back to basic: Trials and tribulations of alkalizing agents in cancer

Frontiers in Oncology2022-11-1426 citations

Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients.

Journal of Clinical Oncology2020-05-203 citations